Repent Pharmacueticals

Repent Pharma backs and funds founders at the earliest stages building the elements and intellectual properties that can become the fabric of our future. A future where innovative and novel biopharmaceutical products openly challenge and disrupt aging, legacy and outdated technologies.


Updates twitter jobs

Science!

What if we could reinvent the Pharmacuetical industry for permissionless innovation and enable the separation of state, drugs and institutions?

Biology

What if we could live long and prosper with nature as our most powerful technology?

computation & engineering

What if we could solve our largest biopharmaceutical challenges?

Knowledge & Data

What if we could untangle Pharmacuetical monopolies and liberate knowledge and data?

this website uses audio to enhance your experience.

What if there was a better way for

What if there was a better way for

REDUCING DRUG FALSE POSITIVES

Developed using state of the art CRISPR-Cas9 Gene Modification Techniques, our TruNegative® Range uses an advanced enzyme based metabolic system to remove and sterilize drug contaminents from samples to reduce false negatives in drug screening. We ensure 100% True Negative Results

Developed using state of the art CRISPR-Cas9 Gene Modification Techniques, our TruNegative® Range uses an advanced enzyme based metabolic system to remove and sterilize drug contaminents from samples to reduce false negatives in drug screening. We ensure 100% True Negative Results

legal notice

BY Repent Capital Management GmbH

Repent Pharma
Oranienburger Straße 1-3
10178 Berlin

General Partners

Ling Ye
Hubert Cheng

Repent Management, LLC

General Manager:
Milton Zhou

Commercial Register and ACN ID

ASIC Register

ACN 00484848

Policies and Resources

Events Code of Conduct and Incident Response Plan
Incident Response Form
SFDR Disclosures
Repent Disclaimer

Contact email

legal@trunegative.com